Healthcare / BiotechnologyBSE
$3.10
-0.06 (-1.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-13000.00 · quality 27.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$235M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.7%
↓Gross Margin
100.0%
↑Debt/Equity
1.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+44.3%
FCF CAGR
—
FCF margin
-193.2%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.6M · net income $-6.8M · FCF $-5.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.6M | $2.6M | $2.3M | $551000.00 | $866949.00 |
| Net Income | $-6.8M | $-6.8M | $-6.6M | $-60.1M | $-104.0M |
| EBITDA | $-3.4M | $-3.4M | $-4.2M | $-4.3M | $-2.5M |
| EPS | -0.09 | -0.09 | -0.09 | -0.79 | -1.37 |
| Gross Margin | 100.0% | 100.0% | 99.7% | -20.3% | 153.3% |
| Operating Margin | -63.0% | -63.0% | -219.5% | -9769.7% | -11734.1% |
| Net Margin | -259.3% | -259.3% | -279.1% | -10904.9% | -11998.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.45 | 1.45 | 1.31 | 1.15 | 0.69 |
| Current Ratio | 0.08 | 0.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.0M | $-5.0M | $46000.00 | $-13000.00 | $978027.00 |
| Returns | |||||
| ROE | -6.7% | -6.7% | -6.1% | -52.9% | -59.9% |
| Valuation | |||||
| P/B | 2.34 | 2.34 | 5.42 | 1.64 | 1.84 |
| Growth & Yield | |||||
| Revenue Growth | 11.0% | 11.0% | 326.3% | -36.4% | — |
| EPS Growth | 0.0% | 0.0% | 88.6% | 42.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → -0.09
Residual
-24.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.